Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

CEL-SCI

DB:LSRM
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LSRM
DB
$429M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • CEL-SCI has significant price volatility in the past 3 months.
LSRM Share Price and Events
7 Day Returns
-0.2%
DB:LSRM
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
90.3%
DB:LSRM
-7.4%
DE Biotechs
-14.2%
DE Market
LSRM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CEL-SCI (LSRM) -0.2% -4.8% 51.5% 90.3% 730% -54%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • LSRM outperformed the Biotechs industry which returned -7.4% over the past year.
  • LSRM outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
LSRM
Industry
5yr Volatility vs Market
Related Companies

LSRM Value

 Is CEL-SCI undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of CEL-SCI to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for CEL-SCI.

DB:LSRM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:LSRM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (3.32%))
1.051
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.051 * 5.44%)
5.33%

Discounted Cash Flow Calculation for DB:LSRM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for CEL-SCI is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:LSRM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.33%)
2020 -21.00 Analyst x1 -19.94
2021 -27.30 Analyst x1 -24.61
2022 -16.90 Analyst x1 -14.46
2023 29.90 Analyst x1 24.30
2024 95.40 Analyst x1 73.60
2025 159.38 Est @ 67.07% 116.75
2026 234.02 Est @ 46.83% 162.75
2027 310.47 Est @ 32.66% 205.00
2028 381.09 Est @ 22.75% 238.90
2029 441.33 Est @ 15.81% 262.68
Present value of next 10 years cash flows $1,024.00
DB:LSRM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $441.33 × (1 + -0.39%) ÷ (5.33% – -0.39%)
$7,691.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $7,691.38 ÷ (1 + 5.33%)10
$4,577.86
DB:LSRM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,024.00 + $4,577.86
$5,601.86
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,601.86 / 37.31
$150.14
DB:LSRM Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:LSRM represents 0.87998x of AMEX:CVM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87998x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 150.14 x 0.87998
€132.12
Value per share (EUR) From above. €132.12
Current discount Discount to share price of €10.38
= -1 x (€10.38 - €132.12) / €132.12
92.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price CEL-SCI is available for.
Intrinsic value
>50%
Share price is €10.38 vs Future cash flow value of €132.12
Current Discount Checks
For CEL-SCI to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • CEL-SCI's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • CEL-SCI's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CEL-SCI's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CEL-SCI's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LSRM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.88
AMEX:CVM Share Price ** AMEX (2020-04-08) in USD $11.79
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CEL-SCI.

DB:LSRM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:CVM Share Price ÷ EPS (both in USD)

= 11.79 ÷ -0.88

-13.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CEL-SCI is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CEL-SCI is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CEL-SCI's expected growth come at a high price?
Raw Data
DB:LSRM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
62.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CEL-SCI, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CEL-SCI's assets?
Raw Data
DB:LSRM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.19
AMEX:CVM Share Price * AMEX (2020-04-08) in USD $11.79
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:LSRM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:CVM Share Price ÷ Book Value per Share (both in USD)

= 11.79 ÷ 0.19

60.9x

* Primary Listing of CEL-SCI.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CEL-SCI is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CEL-SCI's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CEL-SCI has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LSRM Future Performance

 How is CEL-SCI expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CEL-SCI expected to grow at an attractive rate?
  • CEL-SCI's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • CEL-SCI's earnings growth is expected to exceed the Germany market average.
  • CEL-SCI's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:LSRM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LSRM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 62.9%
DB:LSRM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 67.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LSRM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LSRM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-09-30 353 102 121 1
2023-09-30 179 34 43 1
2022-09-30 121 -16 86 2
2021-09-30 5 -27 -19 2
2020-09-30 0 -21 -20 1
2020-04-08
DB:LSRM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -16 -29
2019-09-30 0 -16 -22
2019-06-30 1 -17 -32
2019-03-31 1 -15 -26
2018-12-31 1 -15 -24
2018-09-30 0 -13 -32
2018-06-30 0 -13 -22
2018-03-31 0 -13 -20
2017-12-31 0 -12 -24
2017-09-30 -14 -14
2017-06-30 0 -17 -10
2017-03-31 0 -20 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CEL-SCI's earnings are expected to grow significantly at over 20% yearly.
  • CEL-SCI's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LSRM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from CEL-SCI Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LSRM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-09-30 2.32 2.32 2.32 1.00
2023-09-30 0.83 0.83 0.83 1.00
2022-09-30 1.45 3.14 -0.25 2.00
2021-09-30 -0.41 -0.12 -0.70 2.00
2020-09-30 -0.53 -0.53 -0.53 1.00
2020-04-08
DB:LSRM Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.88
2019-09-30 -0.71
2019-06-30 -1.12
2019-03-31 -1.06
2018-12-31 -1.16
2018-09-30 -1.87
2018-06-30 -1.65
2018-03-31 -1.81
2017-12-31 -2.59
2017-09-30 -1.83
2017-06-30 -1.55
2017-03-31 -1.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CEL-SCI will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CEL-SCI's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CEL-SCI has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LSRM Past Performance

  How has CEL-SCI performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CEL-SCI's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CEL-SCI does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare CEL-SCI's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CEL-SCI's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CEL-SCI's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CEL-SCI Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LSRM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.37 -28.86 8.95
2019-09-30 0.46 -22.13 8.00
2019-06-30 0.57 -32.23 7.15
2019-03-31 0.54 -26.16 5.88
2018-12-31 0.51 -24.42 5.32
2018-09-30 0.48 -31.85 6.33
2018-06-30 0.25 -21.97 7.28
2018-03-31 0.18 -20.42 7.12
2017-12-31 0.08 -24.14 7.09
2017-09-30 -14.43 5.80
2017-06-30 0.15 -10.50 7.95
2017-03-31 0.27 -9.90 8.03
2016-12-31 0.28 -10.32 7.26
2016-09-30 0.29 -11.51 7.59
2016-06-30 0.12 -20.25 6.86
2016-03-31 0.38 -20.81 8.05
2015-12-31 0.54 -24.51 10.37
2015-09-30 0.66 -34.69 13.86
2015-06-30 0.79 -32.05 15.13
2015-03-31 0.42 -30.07 14.66
2014-12-31 0.29 -30.88 13.85
2014-09-30 0.26 -28.47 10.67
2014-06-30 0.21 -22.96 7.99
2014-03-31 0.31 -25.02 7.37 -5.44
2013-12-31 0.26 -12.37 6.93
2013-09-30 0.16 -9.23 6.96
2013-06-30 0.25 -10.10 6.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CEL-SCI has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CEL-SCI has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CEL-SCI improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CEL-SCI's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CEL-SCI has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LSRM Health

 How is CEL-SCI's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CEL-SCI's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CEL-SCI is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CEL-SCI's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of CEL-SCI's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are -6.0502421369506E+15x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CEL-SCI Company Filings, last reported 3 months ago.

DB:LSRM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 6.97 0.00 9.38
2019-09-30 5.13 0.00 8.44
2019-06-30 1.15 0.00 9.49
2019-03-31 0.96 0.00 5.51
2018-12-31 2.71 0.00 6.68
2018-09-30 0.00 0.00 10.31
2018-06-30 -1.25 0.00 2.35
2018-03-31 -3.06 1.18 3.06
2017-12-31 -4.83 0.87 2.14
2017-09-30 -3.34 0.99 2.37
2017-06-30 -5.08 0.33 1.23
2017-03-31 -2.83 0.00 1.53
2016-12-31 4.69 0.00 2.39
2016-09-30 -0.68 0.00 2.92
2016-06-30 -3.77 0.00 5.22
2016-03-31 -2.94 0.00 6.05
2015-12-31 3.53 1.10 10.42
2015-09-30 -4.76 1.10 5.73
2015-06-30 3.93 1.27 11.23
2015-03-31 0.34 1.10 2.61
2014-12-31 11.84 1.10 9.46
2014-09-30 10.44 1.10 8.51
2014-06-30 15.04 1.10 14.29
2014-03-31 7.36 1.10 10.61
2013-12-31 15.11 1.10 13.49
2013-09-30 6.70 1.10 0.04
2013-06-30 7.80 1.10 3.48
  • CEL-SCI's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (9.4% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CEL-SCI has less than a year of cash runway based on current free cash flow.
  • CEL-SCI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.7% each year.
X
Financial health checks
We assess CEL-SCI's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CEL-SCI has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LSRM Dividends

 What is CEL-SCI's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CEL-SCI dividends.
If you bought €2,000 of CEL-SCI shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CEL-SCI's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CEL-SCI's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LSRM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LSRM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CEL-SCI has not reported any payouts.
  • Unable to verify if CEL-SCI's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CEL-SCI's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CEL-SCI has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CEL-SCI's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CEL-SCI afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CEL-SCI has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LSRM Management

 What is the CEO of CEL-SCI's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Geert Kersten
COMPENSATION $8,469,200
AGE 60
TENURE AS CEO 25.2 years
CEO Bio

Mr. Geert R. Kersten, Esq., has been the Chief Executive Officer at CEL-SCI Corporation since February 1995 and serves as its Principal Financial and Accounting Officer. Mr. Kersten joined CEL-SCI Corporation in 1987. Mr. Kersten serves as Treasurer of CEL-SCI Corporation since 1989. He has been involved in the pioneering field of cancer immunotherapy for over two decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He served as a Director of Corporate and Investment Relations for CEL-SCI from February 1987 to October 1987. He served as Vice President of Operations at CEL-SCI Corp. since October 1987. Mr. Kersten served as Chief Operating Officer of CEL-SCI Corp. Mr. Kersten worked as a financial analyst with Source Capital, Ltd. Mr. Kersten has been a Director of CEL-SCI Corporation since December 1988. Mr. Kersten attended George Washington University in Washington, D.C., where he earned a B.A. in Accounting and an MBA with emphasis on International Finance. He also attended law school at American University in Washington, D.C. where he received a Juris Doctor degree. He Graduated from Millfield School in England.

CEO Compensation
  • Geert's compensation has increased whilst company is loss making.
  • Geert's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CEL-SCI management team in years:

16.1
Average Tenure
68
Average Age
  • The average tenure for the CEL-SCI management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Geert Kersten

TITLE
CEO, Principal Accounting & Financial Officer
COMPENSATION
$8M
AGE
60
TENURE
25.2 yrs

Patricia Prichep

TITLE
Senior VP of Operations & Corporate Secretary
COMPENSATION
$2M
AGE
68
TENURE
26.1 yrs

Eyal Talor

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
63
TENURE
10.5 yrs

Dan Zimmerman

TITLE
Senior Vice President of Research & Cellular Immunology
COMPENSATION
$1M
AGE
78
TENURE
10.4 yrs

John Cipriano

TITLE
Senior Vice President of Regulatory Affairs
COMPENSATION
$1M
AGE
77
TENURE
16.1 yrs
Board of Directors Tenure

Average tenure and age of the CEL-SCI board of directors in years:

11.3
Average Tenure
64.5
Average Age
  • The average tenure for the CEL-SCI board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Geert Kersten

TITLE
CEO, Principal Accounting & Financial Officer
COMPENSATION
$8M
AGE
60
TENURE
31.3 yrs

Peter Young

TITLE
Independent Director
COMPENSATION
$822K
AGE
74
TENURE
17.7 yrs

Bruno Baillavoine

TITLE
Independent Director
COMPENSATION
$817K
AGE
67
TENURE
4.8 yrs

Bob Watson

TITLE
Independent Director
COMPENSATION
$817K
AGE
62
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by CEL-SCI individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Feb 20 Buy Robert Watson Individual 26. Feb 20 26. Feb 20 923 €9.96 €9,189
27. Feb 20 Buy Bruno Baillavoine Individual 26. Feb 20 26. Feb 20 923 €9.96 €9,189
27. Feb 20 Buy Peter Young Individual 26. Feb 20 26. Feb 20 923 €9.96 €9,189
27. Feb 20 Buy Daniel Zimmerman Individual 26. Feb 20 26. Feb 20 923 €9.96 €9,189
27. Feb 20 Buy Patricia Prichep Individual 26. Feb 20 26. Feb 20 1,847 €9.96 €18,389
27. Feb 20 Buy Geert Kersten Individual 26. Feb 20 26. Feb 20 4,617 €9.96 €45,967
13. Jan 20 Buy Geert Kersten Individual 10. Jan 20 10. Jan 20 6,631 €6.78 €44,978
28. Oct 19 Buy Geert Kersten Individual 25. Oct 19 25. Oct 19 3,725 €6.05 €22,540
18. Sep 19 Sell John Cipriano Individual 17. Sep 19 17. Sep 19 -8,000 €7.86 €-62,916
29. Aug 19 Sell John Cipriano Individual 28. Aug 19 28. Aug 19 -8,000 €6.34 €-50,711
22. May 19 Buy Peter Young Individual 21. May 19 21. May 19 2,000 €4.48 €8,957
X
Management checks
We assess CEL-SCI's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CEL-SCI has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LSRM News

Simply Wall St News

LSRM Company Info

Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company’s lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia’s Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.

Details
Name: CEL-SCI Corporation
LSRM
Exchange: DB
Founded: 1983
$394,223,771
37,309,877
Website: http://cel-sci.com
Address: CEL-SCI Corporation
8229 Boone Boulevard,
Suite 802,
Vienna,
Virginia, 22182,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX CVM Common Stock NYSE MKT LLC US USD 08. Dec 1983
DB LSRM Common Stock Deutsche Boerse AG DE EUR 08. Dec 1983
Number of employees
Current staff
Staff numbers
0
CEL-SCI employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:08
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/02/14
Last earnings filing: 2020/02/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.